<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03090880</url>
  </required_header>
  <id_info>
    <org_study_id>P150963</org_study_id>
    <secondary_id>2016-002546-23</secondary_id>
    <secondary_id>PHRC</secondary_id>
    <nct_id>NCT03090880</nct_id>
  </id_info>
  <brief_title>Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)</brief_title>
  <acronym>PROVE</acronym>
  <official_title>Long-term Prophylaxis of Venous Thromboembolism With Low-molecular-weight Heparin in Patients With Metastatic Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective randomized open multicenter trial with blinded adjudication of endpoints to
      assess the efficacy of six-month low-dose LMWH for the prevention of symptomatic or
      incidental VTE in patients with stage IV lung cancer and elevated D-dimer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult patients aged ≥ 18 years with stage IV lung cancer and elevated D-dimer will be
      randomized to the experimental or control group.Patients in the control group will receive
      usual care, patients in the experimental group will receive subcutaneous tinzaparin once
      daily for six months. Follow-up visit will take place in outpatient clinic at day 90, day 180
      and day 360. Blood sampling for biomarkers will be performed at inclusion visit and day 90.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>venous thromboembolic events</measure>
    <time_frame>6 months</time_frame>
    <description>all VTE events during the six-month treatment period including:
objectively confirmed symptomatic pulmonary embolism (PE),
objectively confirmed symptomatic lower-limb deep vein thrombosis (DVT) (including iliac and caval thrombosis),
objectively confirmed symptomatic upper extremity DVT,
objectively confirmed incidentally diagnosed PE or proximal DVT
death due to PE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptomatic VTE events</measure>
    <time_frame>6 months</time_frame>
    <description>Objectively confirmed symptomatic VTE and death due to PE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous thromboembolic events</measure>
    <time_frame>12 months</time_frame>
    <description>Objectively confirmed symptomatic or incidental VTE during the 12-months study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleedings</measure>
    <time_frame>6 months</time_frame>
    <description>Major bleeding according to the ISTH criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>6 months</time_frame>
    <description>Overall mortality and causes of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>12 months</time_frame>
    <description>Overall mortality and causes of death</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Risk factors for venous thromboembolism</measure>
    <time_frame>12 months</time_frame>
    <description>Risk fators for venous thromboembolism</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Lung Neoplasm</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>usual care,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tinzaparin sodium</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tinzaparin Sodium</intervention_name>
    <description>Subcutaneous tinzaparin 4,500 IU once daily for six months.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Social security affiliation

          -  Written informed consent

          -  Histologically confirmed stage IV (M1a or M1b) non-small-cell lung cancer, including
             recurrent non-small-cell lung cancer after a period of complete remission

          -  D-dimer &gt; 1,500 µg/L

          -  Planned or ongoing chemotherapy or targeted anticancer therapy

          -  ECOG 0-2

          -  Life expectancy &gt;3 months

        Exclusion Criteria:

          -  Hypersensitivity to heparin

          -  History of heparin-induced thrombocytopenia

          -  Ongoing anticoagulant treatment

          -  VTE at inclusion

          -  Creatinin clearance &lt;30 mL/min

          -  Active bleeding

          -  Platelet count &lt; 100,000 G/L at inclusion

          -  Severe hepatic insufficiency

          -  Cancer treated exclusively with supportive care

          -  Previous inclusion in the trial

          -  Aspirin at daily dosage &gt; 160 mg

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guy Meyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guy Meyer, MD</last_name>
    <phone>+33 156 093 461</phone>
    <email>guy.meyer@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <state>Bretagne</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier régional d'Orléans</name>
      <address>
        <city>Orléans</city>
        <state>Centre</state>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambert</name>
      <address>
        <city>Lille</city>
        <state>Hauts de France</state>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne, Hôpitaux universitaires Paris Seine-</name>
      <address>
        <city>Bobigny</city>
        <state>Ile de France</state>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées Percy</name>
      <address>
        <city>Clamart</city>
        <state>Ile de France</state>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <state>Ile de France</state>
        <zip>92700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Créteil</name>
      <address>
        <city>Créteil</city>
        <state>Ile de France</state>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Versailles André Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <state>Ile de France</state>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <state>Ile de France</state>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Paris Saint-Joseph</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat Claude Bernard</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre cardiologique du Nord</name>
      <address>
        <city>Saint Denis</city>
        <state>Ile de France</state>
        <zip>93200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <state>Ile de France</state>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Ile de France</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Larrey</name>
      <address>
        <city>Toulouse</city>
        <state>Languedoc-Roussillon-Midi-Pyrénées</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <state>Normandie</state>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <state>Nouvelle-Aquitaine</state>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie de l'Ouest</name>
      <address>
        <city>Saint Herblain</city>
        <state>Pays de la Loire</state>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy Genevois</name>
      <address>
        <city>Annecy</city>
        <state>Rhône Alpes</state>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupement Hospitalier Est Hospices civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <state>Rhônes Alpes</state>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint Priest</city>
        <state>Rhônes-Alpes</state>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen, Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <state>Seine Maritime</state>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low-molecular-weight Heparin</keyword>
  <keyword>Tinzaparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

